GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019
04 June 2019 - 8:42PM
GW Pharmaceuticals plc and its U.S. subsidiary Greenwich
Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the
world leader in the science, development, and commercialization of
cannabinoid prescription medicines, today announced that Stephen
Schultz, GW’s Vice President of Investor Relations, will present at
the 40th Annual Goldman Sachs Global Healthcare Conference on
Tuesday, June 11, 2019 at 11:20 a.m. PDT at the Terranea Resort in
Rancho Palos Verdes, California.
A live audio webcast of the presentation will be
available through GW’s corporate website at www.gwpharm.com on the
Investors section under Events & Presentations. A replay will
be available soon after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.Founded in 1998, GW is a
biopharmaceutical company focused on discovering, developing and
commercializing novel therapeutics from its proprietary cannabinoid
product platform in a broad range of disease areas. GW, along with
its U.S. subsidiary Greenwich Biosciences, has received U.S. FDA
approval for EPIDIOLEX (cannabidiol) oral solution for the
treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
or Dravet syndrome in patients two years of age or older and which
is now available by prescription in the U.S. The Company has
submitted a regulatory application in Europe for the adjunctive
treatment of seizures associated with LGS and Dravet syndrome. The
company continues to evaluate EPIDIOLEX in additional rare epilepsy
conditions including Tuberous Sclerosis Complex (TSC) and Rett
syndrome. GW commercialized the world’s first plant-derived
cannabinoid prescription drug, Sativex® (nabiximols), which is
approved for the treatment of spasticity due to multiple sclerosis
in numerous countries outside the United States and for which the
company is now planning a U.S. Phase 3 trial. The Company has a
deep pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 trials for epilepsy,
glioblastoma, and schizophrenia. For further information, please
visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations (U.S.) |
917 280 2424 / 401 500 6570 |
|
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Apr 2024 to May 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about GW Pharmaceuticals PLC (NASDAQ): 0 recent articles
More News Articles